{'fraction_non_alphanumeric': 0.026392961876832845, 'fraction_numerical': 0.0, 'mean_word_length': 5.762376237623762, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Directives for the treatment of HIV infection during pregnancy].


 Although the United States Public Health Service has recommended guidelines for the use of antiretrovirals during pregnancy, the treatments for HIV-positive pregnant women are still inconclusive. Contradictions within the guidelines are explained. The Food and Drug Administration's (FDAs) treatment study classifications and results for HIV-positive women are listed. Fetal risk, animal studies, treatments using protease inhibitors and/or reverse transcriptase inhibitors, and the effect of starting treatment during different trimesters are discussed. Recommendations for when to begin treatment are provided.
